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Abstract
Background: Epigenetic silencing of tumor suppressor genes play important roles in NPC tumorgenesis. Tissue
factor pathway inhibitor-2 (TFPI-2), is a protease inhibitor. Recently, TFPI-2 was suggested to be a tumor suppressor
gene involved in tumorigenesis and metastasis in some cancers. In this study, we investigated whether TFPI-2 was
inactivated epigenetically in nasopharyngeal carcinoma (NPC).
Methods: Transcriptional expression levels of TFPI-2 was evaluated by RT-PCR. Methylation status were investigated
by methylation specific PCR and bisulfate genomic sequencing. The role of TFPI-2 as a tumor suppressor gene in
NPC was addressed by re-introducing TFPI-2 expression into the NPC cell line CNE2.
Results: TFPI-2 mRNA transcription was inactivated in NPC cell lines. TFPI-2 was aberrantly methylated in 66.7%
(4/6) NPC cell lines and 88.6% (62/70) of NPC primary tumors, but not in normal nasopharyngeal epithelia. TFPI-2
expression could be restored in NPC cells after demethylation treatment. Ectopic expression of TFPI-2 in NPC cells
induced apoptosis and inhibited cell proliferation, colony formation and cell migration.
Conclusions: Epigenetic inactivation of TFPI-2 by promoter hypermethylation is a frequent and tumor specific
event in NPC. TFPI-2 might be considering as a putative tumor suppressor gene in NPC.
Background
Nasopharyngeal carcinoma (NPC) is a rare disease in
most parts of the world but is one of the most prevalent
malignasnt tumors and the leading cause of death among
all head and neck cancers in Southern China [1].
Although the major etiological factors, including genetic
susceptibility, environmental carcinogens and Epstein-
Barr virus infection, are well established, the complicated
molecular basis of NPC development and progression
remains unclear [1]. In addition to genetic alterations,
epigenetic inactivation of tumor suppressor genes (TSGs)
by promoter hypermethylation has been increasingly
recognized as a key event for nasopharyngeal carcinogen-
esis [1-4]. Compared with the incidence of DNA muta-
tion and deletion, that of aberrant DNA methylation of
TSGs is high in NPC, which suggests a deep involvement
of aberrant DNA methylation in this rare cancer [1].
Besides having a role as a diagnostic or prognostic bio-
marker, hypermethylated DNA can also be used to reveal
novel TSGs [5]. Identifying aberrant methylated genes
may provide better understanding of the pathogenesis of
NPC, thereby paving the way for the development of
novel tumor markers and therapeutic targets. To discover
novel TSGs in NPC, we conducted a genome-wide
screening for genes downregulated by promoter hyper-
methylation. Analysis of an expression microarray with
RNA from 2 NPC cell lines before and after treatment
with a demethylating agent 5-aza-2’-deoxycytidine
(5-aza-dC) revealed the transcriptional levels of TFPI-2 in
both cell lines significantly upregulated after demethyla-
tion(unpublished data). Thus, TFPI-2 might be a target
gene with expression suppressed by promoter hyper-
methylation in NPC.
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7q22 and encodes a 32-kDa Kunitz-type serine protease
inhibitor that negatively regulates the enzymatic activity
of trypsin, plasmin, and VIIa-tissue factor complex [6-8].
TFPI-2 was found to be abundantly expressed in various
normal human tissues, including seminal vesicles, colon,
stomach, brain, pancreas, oesophagus and liver [9-13].
Several studies have provided suggestive evidence that
TFPI-2 is inactivated or absent during tumor progres-
sion. In addition, expression of TFPI-2 decreases with
an increasing degree of malignancy [10]. Besides gene
locus deletion and aberrant splicing, the mechanism
responsible for TFPI-2 down-regulation in tumor cells
has been majorly attributed to promoter hypermethyla-
tion [14-16]. The promoter region of TFPI-2 contains a
CpG island spanning exon 1 and the 3 transcription
initiation sites [17]. This region harbors sites for several
transcription factors, including SP1, activiting enhancer-
binding protein-1 (AP-1), NF-kB and NF-kB-like site,
and lymphoid transcription factor-1 (Lyf-1) [18]. Tran-
scriptional silencing by promoter hypermethylation of
TFPI-2 was observed in some human cancers [9,19,20].
Recent studies also suggest TFPI-2 may function in the
maintenance of the stability of the tumor environment
and inhibit the growth of neoplasms, thus act as a can-
didate TSG with important roles in carcinogenesis and
metastasis in human cancers [9,12].
In this study, we evaluated the transcriptional levels
and methylation status of TFPI-2 in NPC cell lines and
analyzed the methylation status of TFPI-2 in a set of
NPC primary tumor biopsies. We further addressed the
TSG properties of TFPI-2 in NPC by a series of func-
tional experiments. Several lines of evidence support our
hypothesis that TFPI-2 is epigenetically inactivated in
NPC by promoter hypermethylation and plays a role as
a TSG in NPC tumorigenesis.
Methods
NPC cell lines, primary tumor biopsies and normal
nasopharyngeal epithelia (NNE)
Six NPC cell lines (CNE1, CNE2, TW03, C666-1, HNE1,
and HONE1) were maintained at 37°C in the appropri-
ate medium. The study was approved by the ethics com-
mittee of Guangxi Medical University. In total, 70 NPC
primary tumor biopsies were collected from Department
of Otolaryngology Head and Neck Surgery, First
Affiliated Hospital of Guangxi Medical University (Nan-
ning, China), with informed consent from donors, as
previously described [2,3]. Diagnoses were established
by experienced pathologists according to the World
Health Organization (WHO) classification. We included
12 normal nasopharyngeal epithelial tissues obtained by
tonsillectomy as normal controls. Biopsy samples were
stored in liquid nitrogen before DNA or RNA
extraction.
Semi-quantitative RT-PCR
Total RNA of NPC cell lines and normal NNE was iso-
lated with TRIzol reagent (Invitrogen, USA). First-strand
cDNA was synthesized with M-MLV reverse transcrip-
tase (Promega, USA) according to the manufacturer’s
instructions. Two micrograms of total RNA was used for
each reaction. Primer sequences for TFPI-2 cDNA were
designed according to Norihiro et al, generating a 209-bp
PCR product: TFPI-2-RT-forward: CCAGATGAAGC-
TACTTGTATG and TFPI-2-RT-reverse: GCACATG-
CACGTTTGCAATC [21]. PCR was carried out in a total
volume of 20 μl. The PCR mixture contained 250 pmol
of each primer, 250 pmol deoxynucleoside triphosphate,
1×P C Rb u f f e r ,o n eu n i to fE x T a qH Sp o l y m e r a s e
(Takara, Tokyo), and 2 μl cDNA. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was amplified from the
same cDNA sample as the internal control. The primer
sequences for GAPDH cDNA were: GAPDH-RT-forward:
AAGCTCACTGGCATGGCCTT, and GAPDH-RT-
reverse: CTCTCTTCCTCTTGTGCTCTTG, generating
a 375-bp PCR product. PCR conditions were 94°C for 30
s, 58°C for 30 s (TFPI-2) or 60°C for 30 s (GAPDH), and
72°C for 30 s, 33 cycles for the TFPI-2 gene and 24 cycles
for the GAPDH gene. These cycle numbers fell into the
exponential range of PCR amplification. The amplified
PCR products were then identified on 2% agarose gels.
Images of ethidium bromide-stained agarose gels were
acquired with a CCD camera (Bio-Rad, USA), and semi-
quantitative analysis involved use of the Quantity-one
software, v4.4.0 (Bio-Rad, USA).
Sodium bisulphite modification of genomic DNA
High-molecular-weight genomic DNA was extracted
from cell lines and biopsies by a conventional phenol/
chloroform method. The sodium bisulphite modification
procedure was as described [22] with slight modifica-
tion. In brief, 600 ng of genomic DNA was denatured in
3MN a O Hf o r1 5m i na t3 7 ° C ,t h e nm i x e dw i t h2
volumes of 2% low-melting-point agarose. Agarose/DNA
mixtures were then pipetted into chilled mineral oil to
form agarose beads. Aliquots of 200 μl of 5 M bisulphite
solution (2.5 M sodium metabisulphite, 100 mM hydro-
quinone, both Sigma, USA) were added into each tube
containing a single bead. The bisulphite reaction was
then carried out by incubating the reaction mixture for
4 h at 50°C in the dark. Treatments were stopped by
equilibration against 1 ml of TE buffer, followed by
desulphonation in 500 μl of 0.2 M NaOH. Finally, the
beads were washed with 1 ml of TE buffer and directly
used for PCR.
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The methylation status of the TFPI-2 promoter region
was determined by methylation-specific PCR. Primers
distinguishing unmethylated (U) and methylated (M)
alleles were designed to amplify the sequence of TFPI-2
from - 44 to + 60 bp relative to the transcription start
point [21]: TFPI-2-M-forward: TTTCGTATAAAGC
GGGTATTC; TFPI-2-M-reverse: ACGACCCGCTAAA-
CAAAACG; TFPI-2-U-forward: GGATGTTTGTTTTG-
TATAAAGTG; TFPI-2-U-reverse: AAACATCCAA
AAAAACACCTAAC. Each PCR reaction contained
20 ng of sodium bisulphite-modified DNA, 250 pmol of
each primer, 250 pmol deoxynucleoside triphosphate,
1 × PCR buffer, and one unit of ExTaq HS polymerase
(Takara, Tokyo) in a final reaction volume of 20 μl.
Cycling conditions were initial denaturation at 95°C for
3m i n ,4 0c y c l e so f9 4 ° Cf o r3 0s ,5 4 ° C( M )o r6 0 ° C( U )
for 30 s, and 72°C for 30 s. For each set of methylation-
specific PCR reactions, in vitro-methylated genomic
DNA treated with sodium bisulphite served as a positive
methylation control. A water blank control was also
included. PCR products were separated on 2% agarose
gels, stained with ethidium bromide and visualized
under UV illumination. For cases with borderline
results, PCR analyses were repeated.
Bisulphite genomic sequencing
Sodium bisulphite-modified DNA was subjected to PCR
with primers designed to amplify nucleotides from - 178
to + 166 bp relative to the transcription start point of the
TFPI-2 gene. Primers sequences were designed according
to previous publication by Norihiro et al. [21] TFPI-2-
BISQ-forward: AGGTAGGTTTAATTTTTTAATTTG
and TFPI-2-BISQ-reverse: TACCTATTAACTCCTAAA-
CAAC. PCR was carried out in a total volume of 20 μl,
containing 20 ng of sodium bisulphite-modified DNA as
template, 250 pmol of each primer, 250 pmol of deoxynu-
cleoside triphosphate, 1× PCR buffer, and one unit of
ExTaq HS polymerase (Takara, Tokyo). Cycling conditions
were as follows: initial denaturation at 95°C for 3 min, 40
cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s,
and a final extension at 72°C for 5 min. PCR products
were then gel-purified and cloned with use of the pMD18-
T Vector (Takara, Tokyo) and JM109-competent E. coli
cells. Colonies were grown on agar plates, and 5 colonies
of each sample were randomly selected. Plasmids were
then isolated and purified. Sequencing were carried out
using the BigDye terminator cycle sequencing kit 3.0
(Applied Biosystems, USA) on an ABI 3100 sequencer
according to the manufacturer’s guidelines.
5-aza-dC treatment
Three NPC cell lines (CNE1, CNE2 and C666-1) were
treated with the methyltransferase inhibitor 5-aza-dC.
An amount of 2 × 10
5 cells were seeded on 6-well plates
and incubated for 96 h with 10 μM 5-aza-dC. The med-
ium containing the drug was replaced every 24 h. RNA
was isolated, and subsequent semi-quantitative RT-PCR
was performed as described previously.
Vector construction and transfection
The full-length cDNA sequence of TFPI-2 was from
Origene (USA) and subcloned into the pCMV-Tag3A
mammalian expression vector (Stratagene, USA). Lipo-
fectamine 2000 (Invitrogen, USA) was used to transfect
the TFPI-2-containing plasmids and empty vectors into
CNE2 cells, which lack TFPI-2 expression. Stable clones
of TFPI-2 (CNE2-TFPI-2) or empty vector (CNE2 empty
vector) were obtained by G418 selection (400 μg/ml) for
2 weeks. The expression of exogenous TFPI-2 was con-
firmed by RT-PCR.
Colony formation assay
An amount of 10
5 CNE2 cells was plated in 24-well
plates 24 h before transfection. Lipofectamine 2000 was
used for transfection according to the manufacturer’s
protocol. Cells were transfected with 2 μgp C M V -
Tag3A-TFPI-2 plasmid or empty vector. Transfected
cells were stripped and plated on 60-mm cell culture
dishes 48 h after transfection. After selection by 400 μg/
ml G418 for 2 weeks, Giemsa-stained colonies were
photographed and counted by use of Quantitione soft-
ware, v4.4.0 (Bio-Rad, USA).
Cell proliferation assay
The growth curves of CNE2 cells stably transfected with
TFPI-2 gene (CNE2-TFPI-2) or empty vector (CNE2-
empty vector) were monitored by cell counting. An
amount of 10
4 cells of parent CNE2 cells, CNE2-TFPI-2
and CNE2-empty vector were seeded into 6-well plates.
Cells were trypsinized and stained with a 0.4% trypan
blue solution every 24 h. Dye-exclusive cells were
counted by use of a hemocytometer.
Migration study
Cell migration was assessed by in vitro wound-healing
assay. Stable transfectants of CNE2, CNE2-TFPI-2 and
CNE2-empty vector were cultured on 35-mm dishes for
24-48 h until they reached confluence. A linear wound
track was made by use of a sterile tip. Wounds were
marked and scored in each dish. Plates were then
washed twice with culture medium. Cells migrating into
the wound were photographed under a phase-contrast
microscope after 24 h incubation after wounding.
Annexin V-FITC/PI double-labeled flow cytometry
To determine apoptosis, the expression of Annexin
V-FITC and exclusion of propidium iodide (PI) was
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fected with empty vector and TFPI-2 were collected and
washed with PBS 24 h after transfection, then resus-
pended in 100 μL binding buffer. Samples were incu-
bated with 5 μL Annexin V-FITC in the dark for
10 min at 4°C, then the volume was adjusted to 500 μL
with binding buffer. PI (5 μL) was added, and samples
were incubated for another 10 min at 4°C. Fluorescence
was measured with a flow cytometer (BD FACSCalibur,
USA).
Statistical analysis
SPSS v11.5 (SPSS Inc., Chicago, IL) was used for statisti-
cal analysis. Association between methylated sample data
and clinical pathological features of NPC patients were
analyzed by Pearson chi-square test or Fisher’s exact test.
A p < 0.05 was considered statistically significant.
Results
TFPI-2 mRNA expression is frequently absent in NPC cell
lines
TFPI-2 mRNA expression was evaluated in 6 NPC cell
lines (CNE1, CNE2, TW03, C666-1, HNE1 and HONE1)
and in 12 biopsies of normal NNE by semi-quantitative
RT-PCR. TFPI-2 mRNA was detected in all NNE (Figure 1,
NNE8 and NNE12 as samples). Of the 6 NPC cell lines
tested, 3 lines (CNE1, CNE2 and C666-1) showed complete
silencing of TFPI-2 expression, and decreased expression
was detected in TW03, HNE1 and HONE1 cell lines
(Figure 1).
TFPI-2 promoter is hypermethylated in NPC cell lines and
primary NPC tumors
The methylation status of the TFPI-2 promoter in NPC
cell lines was detected by methylation-specific PCR assay.
The TFPI-2 promoter was hypermethylated in 4 of 6
NPC cell lines (CNE1, CNE2, C666-1 and HONE1); only
TW03 and HNE1 cells were unmethylated (Figure 2). All
12 normal nasopharyngeal epithelial tissues showed
unmethylated TFPI-2 promoters. We further evaluated
the methylation status of the TFPI-2 promoter in 70
NPC primary tumors. Promoter hypermethylation was
detected in 88.6% (62/70) of the NPC primary tumors
but in none of the 12 NNE. Representative samples are
shown in Figure 3. Unmethylated amplicons were found
in some but not all of the NPC biopsy samples likely
because of the existence of non-malignant cells such as
stromal cells in a fraction of the samples.
CpG sites in the TFPI-2 promoter are heavily methylated
in NPC cell lines and NPC biopsies
To detect the methylation status of individual CpG sites
in the NPC samples relative to the normal control biop-
sies, the detailed methylation status of the TFPI-2
promoter region - 178 to + 166 bp relative to the trans-
lation start site of the TFPI-2 gene was determined by
bisulphite genomic sequencing in 2 NPC cell lines
(CNE2 and C666-1), 2 NPC biopsies (NPC24 and
NPC34) and 1 NNE sample (NNE7). The relevant
344-bp TFPI-2 promoter region contained 31 CpG sites.
For each sample shown in Figure 4, the sequence of 5
representative clones is shown. All 31 CpG sites were
heavily methylated in cell lines CNE2 and C666-1, in
which TFPI-2 expression was silenced (Figure 4). Dense
methylation of CpG dinucleotides was also observed in
the 2 NPC biopsies tested. The presence of some
unmethylated clones in the CNE2 and C666-1 cell lines
may reflect heterogeneity in the original cell lines. The
NNE samples were completely free of methylation.
Figure 1 RT-PCR analysis of mRNA expression of TFPI-2 in NPC
cell lines and normal nasopharyngeal epithelia (NNE) samples.
The data are representative of 2 independent experiments.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and water
were used as internal and blank controls, respectively.
Figure 2 Methylation status of the TFPI-2 promoter region in
NPC cell lines and normal nasopharyngeal epithelia (NNE). The
data are representative of 2 independent experiments. In vitro-
methylated DNA was used as a methylation-positive control and
DNA from normal lymphocytes was used as an unmethylated-
positive control. Water was included as a blank control. MSP:
methylation-specific PCR; U: unmethylated alleles; M: methylated
alleles. PC: positive control.
Figure 3 Methylation-specific PCR analysis of the TFPI-2
promoter region in NPC primary tumors and normal
nasopharyngeal epithelia (NNE). Four NPC primary tumors (NPC
13, 16, 24 and 34) and 4 NNE (NNE3, 7, 9 and 12) are shown as
examples. U: unmethylated alleles; M: methylated alleles. The data
are representative of 2 independent experiments.
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our bisulphite conversion of genomic DNA was com-
plete and thus supports the reliability of our methyla-
tion-specific PCR results.
Transcription of TFPI-2 can be restored by 5-aza-dC
treatment
T oc o n f i r mt h a tm e t h y l a t i o no ft h eTFPI-2 gene is
directly responsible for the loss of TFPI-2 transcription,
the TFPI-2-silenced NPC cell lines (CNE1, CNE2 and
C666-1) were treated with the demethylating agent
5-aza-dC for 4 days. Transcriptional expression was
restored in all 3 cell lines (Figure 5).
Clinico-pathological significance of TFPI-2 promoter
hypermethylation
Analysis of the association of TFPI-2 promoter hyper-
methylation and clinico-pathological parameters of NPC
patients revealed no significant association of presence of
methylated or unmethylated TFPI-2 promoters and age,
sex, cancer staging, or pathological subtypes (Table 1).
TFPI-2 suppresses cell proliferation and colony formation
and inhibits cell migration in NPC cells
To assess whether TFPI-2 might possess properties as a
tumor suppressor gene in NPC, we examined the effect
of TFPI-2 on clonogenicity, cell proliferation, and cell
mobility. The colony-formation efficiencies were evalu-
ated by monolayer culture. The number of colonies
formed by CNE2-TFPI-2 cells was less than that by
CNE2-empty vector cells (p <0 . 0 5 )( F i g u r e7 ) .T h i s
finding was further supported by cell proliferation assay.
CNE2-TFPI-2 cells grew significantly slower than CNE2
parental cells and CNE2-empty vector cells (Figure 6).
Wound healing assay was carried out to measure cell
mobility by comparing the scratching healing efficiency
of CNE2-TFPI-2 cells and CNE2 empty vector cells. The
CNE2-TFPI-2 cells moved slower into the scratched
areas than did CNE2-empty vector control cells, which
suggests that ectopic expression of TFPI-2 inhibits the
motility of NPC cells (Figure 8).
TFPI-2 induces apoptosis in NPC cells
The degree of early apoptosis was represented as a per-
centage of the annexin V-FITC-positive and PI-negative
cells, and late apoptosis was quantitatively represented
as a percentage of the annexin V-FITC-positive and PI-
positive cells. The overall apoptosis rate was the sum of
early and late apoptosis subpopulations. The apoptosis
rate in CNE2-TFPI-2 cells (63.45% ± 8.28%) was signifi-
cantly higher than that in the empty vector control
(38.07% ± 12.38%) in 5 independent tests (Figure 9),
which suggests that TFPI-2 induces apoptosis in NPC
cells.
Discussion
Previously, we analyzed expression microarray data
before and after treatment with demethylating agent in
2 NPC cell lines and speculated that the TFPI-2 gene
may be downregulated by promoter hypermethylation in
NPC cells. TFPI-2, also known as placental protein 5
and matrix-associated serine protease inhibitor [7,23], is
a novel serine protease inhibitor [7,24]. It was reported
to be involved in tumorigenesis and metastasis in several
types of cancers [24]. Suppression of TFPI-2 gene
expression is frequently found in melanoma, liver and
pancreatic cancer [9,25,26]. Downregulation of TFPI-2
mRNA and protein by promoter hypermethylation has
been confirmed by RT-PCR, immunostaining, methyla-
tion specific PCR and bisulfate genomic sequencing
[9,27]. In this study, hypermethylation of the TFPI-2
promoter was detected in 4 of 6 (66.7%) NPC cell lines.
We also showed a high frequency (88.6%) of TFPI-2
promoter hypermethylation in NPC primary tumor
biopsies but not in the NNE tissues, which implied that
transcriptional silencing of the TFPI-2 pathway might
be involved in NPC tumorigenesis. As well, we found a
high frequency of promoter hypermethylation of TFPI-2
in early stage (I and II) NPC, which indicates that this
might be an early event in NPC carcinogenesis. In
Figure 4 Bisulphite genomic sequencing of NPC cells, tumor
biopsies and NNEs. Bisulphite genomic sequencing of the
methylation status of the 31 CpG sites within the TFPI-2 promoter in
2 NPC cell lines (CNE2 and C666-1), 2 NPC biopsies (NPC24 and
NPC34) and 1NNE biopsy (NNE7). Five randomly selected clones
were sequenced for each sample. Open and filled circles represent
unmethylated and methylated CpG sites, respectively. Circles were
partially filled according to the percentage of methylation of the
CpG site. The frames show the CpG pairs covered by methylation-
specific PCR primers.
Figure 5 Treatment with 5-aza-dC restores TFPI-2 expression in
3 NPC cell lines. TFPI-2 mRNA expression level was evaluated by
RT-PCR. GAPDH was amplified as an internal control. NNE8 was used
as positive control. A water blank control was also included.
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in NPC cell lines and primary tumors, the absence of
promoter hypermethylation in 12 histological NNE tis-
sues showed that hypermethylation of TFPI-2 promoter
is not necessary to maintain the normal phenotype in
the nasopharyngeal epithelium. Thus, hypermethylation
of TFPI-2 is a frequent and highly tumor-specific event
in NPC. Such characteristics may suggest TFPI-2 methy-
lation as a molecular marker for NPC.
By bisulfite genomic sequencing assay, we found
methylation degrees ranging from 60% to 100% in most
of the CpG dinucleotides in the TFPI-2-silenced NPC
cell lines CNE2 and C666-1. A heavy degree of methyla-
tion was also observed in NPC primary tumors, despite
Table 1 Associations between TFPI-2 promoter methylation and clinicopathological indices of NPC
Number of patients Promoter methylation status
Methylated Unmethylated Statistic significance
Age
< 60 58 52 (89.7%) 6 NS
≥ 60 12 10 (83.3%) 2
Gender
Male 48 44 (91.7%) 4 NS
Female 22 18 (81.8%) 4
Stage*
I-II 28 24 (85.7%) 4 NS
III-IV 42 38 (90.5%) 4
Histological subtype
Keratinizing squamous cell carcinoma 8 6 (75%) 2 NS
Non-keratinizing carcinoma 62 56 (90.3%) 6
Lymph node metastasis
Presence 58 50 (86.2%) 8 NS
Absence 12 12 (100%) 0
*: Staging according to International Union Against Cancer (UICC).
NS: not statistically significant.
Figure 7 TFPI-2 inhibits colony formation in NPC cells.T o p :
CNE2 cells were transfected with empty vector or TFPI-2-expressing
plasmids and selected with G418 for 2 weeks. The experiment was
done in triplicate and the error bars represent standard deviations
(p < 0.05).
Figure 6 TFPI-2 inhibits NPC cell proliferation.A :R T - P C R
validation of stable transfectance of CNE2-TFPI-2 or CNE2-Empty
vector. B: Proliferation curves of CNE2 cells, stable transfectants of
CNE2-TFPI-2 and CNE2-empty vector. Cells were counted every 24 h
for 6 days.
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samples without micro-dissection. Moreover, TFPI-2
was completely restored by demethylation treatment in
all 3 TFPI-2-silenced NPC cell lines. In this context, epi-
genetic inactivation of TFPI-2 by promoter hypermethy-
lation is a major, if not the only, mechanism responsible
for the loss of TFPI-2 expression in NPC.
Although promoter hypermethylation of TFPI-2 is fre-
quently found in NPC, it is not associated with sex, age,
nodal metastasis or cancer stage in our series. This find-
ing is inconsistent with observations in pancreatic and
non-small-cell lung cancer; a high methylation rate of
TFPI-2 was reported in pancreatic cancer patients with
liver metastasis [25]. In non-small-cell lung cancer,
TFPI-2 promoter hypermethylation was frequently
found in patients with late-stage cancer (stages III and
IV) and with lymph node metastases [27]. These find-
ings suggest that the prognostic value of promoter
hypermethylation of TFPI-2 is tissue-specific.
The tumor-suppressive functions of TFPI-2 have been
demonstrated in several human malignancies such as
lung cancer, prostate cancer, glioma, melanoma and eso-
phageal carcinoma. Ectopic expression of TFPI-2 protein
in these cancer cell lines negatively regulates colony
formation and inhibits cell proliferation [12,27-30].
Additional studies have shown that TFPI-2 inhibits
tumor-related angiogenesis and some members of the
extracellular matrix (ECM) therefore implicates tumor
invasion and progression [8,12,17,29]. Degradation of
the ECM is an essential process for tumor invasion and
metastasis and involves various matrix-degrading protei-
nases. The most important proteolytic ECM enzymes
are matrix metalloproteinases (MMPs), and upregulated
MMP expression has been demonstrated to be strongly
associated with the progression of malignancy in several
types of cancer, including NPC [31,32]. By inhibiting
plasmin, TFPI-2 effectively decreases the activation of
MMP-1, MMP-3 and MMP-9 and reduces the invasive
potential of several cancer cell lines [9,12,33,34]. In
accordance with previous studies, we demonstrated that
ectopic expression of TFPI-2 significantly inhibited cell
proliferation, colony formation and migration in NPC
cells. We also demonstrated that restoration of TFPI-2
induces apoptosis in NPC cells. All these evidence
strongly implies that TFPI-2 is a putative TSG and plays
a role in nasopharyngeal carcinogenesis.
Methylation-mediated inactivation is reversible, up-reg-
ulating TFPI-2 by demethylating agent may reverse the
malignant phenotype of tumor cells. Therefore TFPI-2
can serve as a novel target for gene therapy in NPC treat-
ment. On the other hand, TFPI-2 functions extracellu-
larly as a secreted protein. Treatment with recombinant
TFPI-2 protein inhibited tumor growth and metastasis of
esophageal cancer [12]. Thus, TFPI-2 protein might be
used directly as an anticancer drug. Further studies will
be necessary to explore the great therapeutic potential of
TFPI-2 in NPC and other cancer.
Conclusions
The present work demonstrated that epigenetic inactiva-
tion of TFPI-2 by promoter hypermethylation is a
Figure 8 TFPI-2 inhibits cell mobility in NPC cells.T h ec e l l
motility of the CNE2-empty vector and CNE2-TFPI-2 was determined
by wound healing assay. At 24 h after scratching, the CNE2-TFPI-2
cells spread significantly slower than did CNE2 empty vector cells.
All experiments were performed in triplicate, and data from
representative experiments are shown.
Figure 9 TFPI-2 induces apoptosis in NPC cells.A :C N E 2c e l l s
were transfected with empty vector and TFPI-2, then stained with
annexin V-FITC and PI and subjected to flow cytometry.
Fluorescence dot blots of annexin V-positive (horizontal axis) and
PI-positive (vertical axis) cells are shown. B: Cells that were positively
stained by annexin V-FITC only (early apoptosis) and positive for
both annexin V-FITC and PI (late apoptosis) were quantitated, and
both subpopulations were considered as apoptotic cells. The bar
graph shows the average in 5 experiments. Error bars show
standard deviations.
Wang et al. BMC Cancer 2010, 10:617
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Page 7 of 8frequent and tumor specific event in NPC and TFPI-2
might be considering as a putatitive tumor suppressor
gene in NPC.
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